Meeting
2021 ASCO Annual Meeting
ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
Authors
Susana N. Banerjee
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
Susana N. Banerjee , Bradley J. Monk , Els Van Nieuwenhuysen , Kathleen N. Moore , Ana Oaknin , Michel Fabbro , Nicoletta Colombo , David M. O'Malley , Robert L. Coleman , Jonathan A. Pachter , Andrew G. Koustenis , Gloria Patrick , Lorna Leonard , Rachel N. Grisham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04625270
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5603)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5603
Abstract #
TPS5603
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
First Author: Susana N. Banerjee
Poster
2023 ASCO Annual Meeting
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
First Author: Susana N. Banerjee
First Author: Bradley J. Monk
Poster
2023 ASCO Annual Meeting
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
First Author: Joshua E. Reuss